Document:

Exhibit 10.18
	​

	​

	
	11 Hurley Street
Cambridge, MA 02141

P 617-401-9000
F 617-494-0985

September 25, 2020
Lisa A. Michaels, MD
Re: Offer of Employment
Dear Lisa,
On behalf of Editas Medicine, Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter (the “Offer Letter”) is to set forth the terms of your employment with the Company, should you accept our offer.
I am pleased to offer you the position of Executive Vice President, Chief Medical Officer at the Company, reporting to the Chief Executive Officer. Your base salary will be at the rate of $18,076.92 per biweekly pay period (equivalent to an annualized base salary of $470,000.00), subject to tax and other withholdings as required by law. Such base salary may be adjusted from time to time in accordance with normal business practice and in the sole discretion of the Company. You will be employed on a full-time basis. Your effective date of hire as an employee (the “Start Date”) will be November 9th, 2020. You shall work out of the Company’s office at One Main Street, 8th Floor, Cambridge, MA 02142 and shall travel as required by your job duties.
Following the end of each fiscal year and subject to the approval of the Company’s Board of Directors (the “Board”), or a duly authorized committee thereof, you will be eligible for a retention and performance bonus, targeted at 45% of your annualized base salary, based on your and the Company’s performance during the applicable fiscal year as determined by the Board (or such committee) and in accordance with certain corporate goals determined by the Board (or such committee), in each case, in its sole discretion. Such bonus shall be pro-rated for any partial year and shall not be payable if your Start Date is within the last quarter of the fiscal year. You shall not be entitled to any bonus if you voluntarily terminate your employment with the Company, other than for Good Reason, as such term is defined in the Company’s Severance Benefits Plan (as amended and/or restated from time to time, the “Severance Benefits Plan”), prior to the date such bonus is distributed, as it also serves as an incentive to remain employed by the Company, provided, that the Company will award and pay any bonus for the prior calendar year no later than March 15th of the next succeeding fiscal year.
Confidential
​

You will receive a one-time sign on bonus of $150,000.00, less applicable taxes and withholdings (the “Signing Bonus”), which will be paid to you in the first regular payroll following your Start Date. If, within one (1) year after your Start Date, either (i) you voluntarily terminate your employment with the Company for any reason other than for Good Reason or (ii) if the Company terminates your employment because it has determined in its sole discretion that you have (a) engaged in fraud, misappropriation, or embezzlement, (b) materially breached any Company policy or any agreement by and between you and the Company; (c) committed one or more acts constituting either a felony or any crime involving dishonesty or moral turpitude; or (d) failed to perform your duties and/or responsibilities to the Company’s satisfaction, you agree to repay the Company within thirty (30) days of your separation from employment with the Company, the entire Signing Bonus paid by the Company. You further acknowledge and agree that the Company may deduct from any amounts due to you from the Company (including without limitation any salary, bonuses, severance or separation pay, and expense reimbursements) up to the full amount of the Signing Bonus owed to the Company, subject to applicable law. If such deduction does not fully satisfy the amount of reimbursement due, or if the Company elects not to take such deduction, you agree to repay the remaining unpaid balance to the Company within thirty (30) days of your separation from employment with the Company. By signing and returning this Offer Letter, you agree to repayment of the Signing Bonus as provided for in this paragraph, and you further agree to execute any documents that may be requested by the Company to memorialize any deductions that you have authorized herein.
You will be eligible for six (6) months of temporary living costs at a rate of $7,000.00 per month less applicable taxes and withholdings (the “Housing Allowance”).
In addition, you will also be eligible to receive up to $125,000.00 less applicable taxes and withholdings (the “Relocation Amount”) to support you in your relocation to the Cambridge, MA area You must submit an expense summary and adequate supporting documentation for all qualified expenses no later than the end of the month following the month in which the expense was incurred, to include by way of example:
		•	Packing and shipping your household goods and personal effects to Massachusetts;

		•	Travel, excluding meals, to your new home in Massachusetts;

		•	Disconnecting and connecting utilities; and

		•	Up to 30 days of storage and insurance expenses for household goods and personal effects.

The applicable portion of the Relocation Amount will be paid to you no later than the end of the month following your provision of supporting documentation.
All reimbursements and in-kind benefits provided hereunder shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in- kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during your lifetime (or during a shorter period of time specified herein), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year.

If, within twelve (12) months after the Company’s final payment of the Relocation Amount, either (a) you voluntarily terminate your employment with the Company for any reason, other than for Good Reason, or (b) if the Company terminates your employment for Cause, you agree to repay the Company within thirty (30) days of your separation from employment with the Company, the entire Housing Allowance and Relocation Amount paid by the Company. If, after twelve (12) months but before twenty- four (24) months after the Company’s final payment of the Relocation Amount, you voluntarily terminate your employment with the Company for any reason, other than for Good Reason, or if the Company terminates your employment for Cause, you agree to repay the Company within thirty (30) days of your separation from employment with the Company, an amount prorated starting at fifty percent (50%) of the Housing Allowance and Relocation Amount paid by the Company. You further acknowledge and agree that the Company may deduct from any amounts due to you from the Company (including without limitation any salary, bonuses, severance or separation pay, and expense reimbursements) up to the full amount of the Housing Allowance and Relocation Amount owed to the Company, subject to applicable law. If such deduction does not fully satisfy the amount of reimbursement due, or if the Company elects not to take such deduction, you agree to repay the remaining unpaid balance to the Company within thirty (30) days of your separation from employment with the Company. By signing and returning this Offer Letter, you agree to repayment of the Housing Allowance and Relocation Amount as provided for in this paragraph, and you further agree to execute any documents that may be requested by the Company to memorialize any deductions that you have authorized herein. For purposes of this Offer Letter, “Cause” shall have the respective definitions presently set forth in the Company’s Severance Benefits Plan (as amended and/or restated from time to time, the “Severance Benefits Plan”).
Subject to approval of the Board or a duly authorized committee thereof, you shall be granted (i) a stock option to purchase 120,000 shares of the Company’s common stock (the “Option”) at an exercise or purchase price equal to the fair market value of the Company's common stock on the date of grant and (ii) restricted stock units (“RSU,” together with the Option, the “Equity Awards”) in the amount of 20,000 units. The Option will vest over four (4) years at the rate of 25% on the first anniversary of the Start Date, and an additional 2.0833% of the original number of shares at the end of each successive month following the first anniversary of the Start Date until the fourth anniversary of such date, provided you remain employed by the Company on the vesting dates. The RSU will vest over four (4) years at the rate of 25% of the original number of RSUs on the first anniversary of the Start Date, and an additional 25% of the original number of RSUs will vest at the end of each successive anniversary date of your Start Date until the fourth anniversary of such date, provided you remain employed with the Company on the vesting dates. The Equity Awards are being granted pursuant to Nasdaq Listing Rule 5635(c)(4) as an inducement for you to enter into employment with the Company.  The Equity Awards will be brought to the Board of Directors (or a duly authorized committee thereof) for approval on or after the date you begin employment with the Company.  The Equity Awards will be evidenced in writing by, and subject to the terms of an inducement stock option agreement and an inducement restricted stock unit agreement, as applicable.
You may participate in any benefit programs that the Company establishes and makes available to its employees from time to time, provided you are eligible under (and subject to all provisions of) the plan documents governing those programs. Additionally, you will be eligible for paid vacation 

and holidays in accordance with Company policy. Please see the enclosed “2020 Benefits Overview” for detailed information on our benefits and related policies, which currently include 13 paid holidays and a flexible time-off program. The benefit programs made available by the Company, and the rules, terms and conditions for participation in such benefit plans, may be changed by the Company at any time without advance notice. For clarification purposes, under the “Severance Benefits Plan”, as an Executive Vice President, you are eligible to receive benefits as defined for the role of “Other C Level Officer”.
You will be required to execute a Non-Solicitation, Non-Competition, Confidentiality and Assignment Agreement in the form attached hereto as Exhibit A (the “Agreement”) and, prior to your Start Date, a Durable Automatic Sale Instruction Letter in the form attached hereto as Exhibit B. You acknowledge that your eligibility for the Housing Allowance and Relocation Amount Equity Awards referenced herein are contingent upon your agreement to the non- competition provisions set forth in the Agreement. You further acknowledge that such consideration was mutually agreed upon by you and the Company, is fair and reasonable, and is in exchange for your compliance with such non-competition obligations.
In making this offer, the Company understands, based on representations made by you, that you are not under any obligation to any former employer or any person or entity which would prevent, limit, or impair in any way your acceptance of this offer or employment or the performance by you of your duties as an employee of the Company. In accepting this offer you represent and warrant the foregoing to be true and correct (i) that in connection with providing services to the Company you will not use any confidential and/or proprietary information of any third party, including, without limitation, any former employer, or bring any biological or other materials to the Company and (ii) the Agreement was provided to you by the earlier of (A) the date we sent you this Offer Letter or (B) ten (10) business days before your Start Date.
You agree to provide to the Company, within three days of your hire date, documentation of your eligibility to work in the United States, as required by the Immigration Reform and Control Act of 1986. You may need to obtain a work visa in order to be eligible to work in the United States.
If that is the case, your employment with the Company will be conditioned upon your obtaining a work visa in a timely manner as determined by the Company.
It is understood that you are an “at-will” employee. You are not being offered employment for a definite period of time or pursuant to an employment contract, and either you or the Company may terminate the employment relationship at any time and for any reason, with or without cause, or prior notice and without additional compensation to you, except as provided in the
You will be eligible to participate in the Company’s Severance Benefits Plan, as amended, a copy of which is attached hereto as Exhibit C (the “Severance Benefits Plan”), at the applicable level referenced in such plan. Your eligibility under the Severance Benefits Plan is subject to the terms and conditions thereof.

This Offer Letter and the Agreement referenced above constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (formal or informal, whether written, oral or implied) between you and the Company. This Offer Letter may not be amended or modified except by an express written agreement signed by both you and a duly authorized officer of the Company, although your job duties, title, reporting relationship, compensation and benefits may change from time to time in the Company's sole discretion and provided that the "at-will" nature of your employment may only be changed by a written agreement signed by you and the Company’s Chief Executive Officer, which expressly states the intention to modify the at-will nature of your employment. Nothing in this Offer Letter shall be construed as an agreement, either express or implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company, except to the extent you are eligible for post-employment benefits under the Severance Benefits Plan.
As an employee of the Company, you will be required to familiarize yourself and comply with all Company policies and procedures. Violations of the Company's policies may lead to immediate termination of your employment. Further, the Company's premises, including all workspaces, furniture, documents and other tangible materials, together with all information technology resources of the Company (including computers, portable devices, data and other electronic files (whether in hard copy or electronic form), and all internet and email communications) are subject to oversight and inspection by the Company at any time. Company employees shall have no expectation of privacy with regard to any Company premises, materials, resources or information.
The Company’s offer of at-will employment is contingent upon your authorization and successful completion of background and reference checks as may be requested by the Company. If requested by the Company, you will be required to execute authorizations for the Company to obtain consumer reports and/or investigative consumer reports and use them in conducting background checks as a condition to your employment. The Company may obtain background reports both pre-employment and from time to time during your employment with the Company, as necessary.
Please indicate your acceptance of this offer by signing the enclosed copy of this Offer Letter and the Agreement via the electronic signature tool, no later than October 1, 2020.
Please know that we are truly excited at the prospect of your becoming part of the Editas team and your leadership in helping to build what we hope will be an exceptional organization, one that is both a scientific pioneer and that delivers transformative medicines to many patients. We believe that you will be a fundamental part of turning that aspiration into reality.
	​

	Very truly yours,

	Editas Medicine, Inc.

	​

	/s/ Clare Carmichael

	Signature: Clare Carmichael

	Chief Human Resources Officer

The foregoing correctly sets forth the terms of my employment by the Company. I am not relying on any other representation, except as set forth in this Offer Letter.
	​

	/s/ Lisa A. Michaels

	Signature: Lisa Michaels

	Chief Human Resources Officer

​Exhibit 10.24
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions.
FIRST AMENDMENT TO SPONSORED RESEARCH AGREEMENT
This Amendment (the “SRA Amendment”) is entered into as of January 11, 2021 (the “SRA Amendment Effective Date”), by and between The Broad Institute, Inc., a non-profit Massachusetts corporation, with a principal office at 415 Maine Street, Cambridge, MA 02142 (“Broad”) and Editas Medicine, Inc., a Delaware corporation, located at 11 Hurley Street, Cambridge, MA 02141 (“Editas”), and amends that certain Sponsored Research Agreement, dated as of June 7, 2018 (the “Sponsored Research Agreement”). Broad and Editas may be referred to herein individually as a “Party” and collectively as the “Parties.”
RECITALS
Whereas, Broad and Editas are party to the Sponsored Research Agreement; and
Whereas, the Parties wish to amend the Sponsored Research Agreement as follows;
Now, Therefore, in consideration of the mutual covenants and agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
		1.	Section 3.5.1 of the Sponsored Research Agreement is amended by adding the following to the end of such section:

“Notwithstanding the foregoing, in the event that the Company qualifies as a Well-Known Seasoned Issuer as defined in the Securities Act, then the Company may, upon notice to Broad, issue such number of shares of Common Stock that are Public Securities as calculated in accordance with the immediately preceding sentence (which shares, for the avoidance of doubt, shall not be registered under the Securities Act at issuance) no later than [**] after the applicable Trigger Date in full or partial satisfaction of a Research Payment, so long as the Company uses its commercially reasonable efforts to file a prospectus supplement that constitutes a Resale Registration Statement on the Trading Day on which such shares are issued and such prospectus supplement is filed no later than [**] following such issuance.  Any shares issued pursuant to the prior sentence shall be deemed Note Shares for purposes of this Agreement.”
		2.	Effect of Amendment.  Except as specifically amended herein, the Sponsored Research Agreement is hereby ratified and confirmed and shall remain in full force and effect. Upon the effectiveness of this SRA Amendment, on and after the date hereof, each reference in the Sponsored Research Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import, and each reference in the other documents entered into in connection with each such agreement, shall mean and be a reference to such agreement, as amended hereby.

		3.	Governing Law.  This SRA Amendment shall be construed in accordance with, the substantive laws of the Commonwealth of Massachusetts, without giving effect to any choice or conflict of law provision.

		4.	Counterparts.  This SRA Amendment may be executed and delivered by electronic signature and in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

[Remainder of Page Intentionally Left Blank]
​
​

In Witness Whereof, the Parties hereto have caused this SRA Amendment to be executed and entered into by their duly authorized representatives as of the SRA Amendment Effective Date.
	​

	​

	​

	​

	​

	The Broad Institute, Inc.
	    
	Editas Medicine, Inc.

	​
	​
	​
	​
	​

	By:
	/s/ Issi Rozen
	​
	By:
	/s/ Cynthia Collins

	​
	​
	​
	​
	​

	Name: 
	Issi Rozen
	​
	Name: 
	Cynthia Collins

	​
	​
	​
	​
	​

	Title:
	Chief Business Officer
	​
	Title:
	President and Chief Executive Officer

​

Signature Page to SRA Amendment

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}]]